Seeking AlphaCodex · 实盘不做把握 5/10
北京时间·🕒 发布 19:11:31时区推断·⟳ 抓取 19:16:47·⚡ 决策 07-22 21:47:35 +2h30m·96.8 天前
Summit披露依沃西肺癌后续OS数据，西方患者HR由0.79改善至0.76
依沃西后续数据方向为利好，西方患者更长随访HR由0.79改善至0.76且未见新增安全信号。
📄 原文Seeking Alpha↗ 原文
Summit updates survival data for Akeso-partnered lung cancer drug
Summit Therapeutics (SMMT) lost ~1% in the premarket on Wednesday after the company shared the latest data on overall s…
不做 康方生物（09926.HK）
依沃西核心OS利好已在ASCO和6月专家访谈窗口充分传播，本条只是后续HR小幅改善更新；康方当日已涨4.55%，不追。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-22 · 扩散 medium · price-in 风险 high ↗
消息传播链
- 2026-05-31官方确认/否认ASCO/公司披露相关数据声称一手 · 未核验内部KB显示依沃西HARMONi-6中期OS强数据已在ASCO窗口公布并被市场讨论。
- Seeking Alpha报道更长随访后西方患者HR由0.79改善至0.76且无新增安全信号。市场反应:康方生物当日收涨4.55%，Summit盘中涨6.43%。
关键理由
- 依沃西后续数据方向为利好，西方患者更长随访HR由0.79改善至0.76且未见新增安全信号。
- 内部KB显示依沃西强OS数据在2026年5月底ASCO及6月专家访谈已被充分讨论，本条更像后续更新而非全新临床突破。
- 康方生物（09926.HK）当日已涨4.55%，近20日围绕依沃西数据多次大幅波动，追高性价比不足。
主要风险
- 若后续正式监管申报或欧美商业化条款超预期，可能重新形成新催化。
反向证据
- 做多前查反向 · 来源 kb_search · 日期 2026-06-30 · 影响 weakens
KB已有6月专家访谈和ASCO相关讨论，削弱新鲜度。
检索:康方生物 依沃西 ivonescimab overall survival hazard ratio 0.76 Summit 2026 原文 ↗
工具调用 · 历史记录,结果未知(4 种)
- search_processed_events · 结果未知
- stock_quote · 结果未知
- kb_search · 结果未知
- validate_order · 结果未知
原文全文
展开原文 · 1,101 字
Summit Therapeutics (SMMT) lost ~1% in the premarket on Wednesday after the company shared the latest data on overall survival from a late-stage trial for ivonescimab, a lung cancer therapy it is developing with Chinese biotech Akeso (AKESF).
Based on
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.
Entering text into the input field will update the search result below
Entering text into the input field will update the search result below
Quick Insights
The updated trial data show continued favorable overall survival trends for ivonescimab, with improved hazard ratios over longer follow-up, suggesting consistent benefit across Western and Asian patient subgroups.
Hazard ratios improved from 0.79 to 0.76 with longer follow-up in Western patients, aligning with results in Asian patients and indicating growing evidence of treatment benefit.
The latest analysis found no new safety signals, supporting a favorable safety profile.
Based on
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.
Entering text into the input field will update the search result below
Entering text into the input field will update the search result below
Quick Insights
The updated trial data show continued favorable overall survival trends for ivonescimab, with improved hazard ratios over longer follow-up, suggesting consistent benefit across Western and Asian patient subgroups.
Hazard ratios improved from 0.79 to 0.76 with longer follow-up in Western patients, aligning with results in Asian patients and indicating growing evidence of treatment benefit.
The latest analysis found no new safety signals, supporting a favorable safety profile.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。